Insmed Incorporated (INSM) has a negative trailing P/E of -26.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 140.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.74%, forward earnings yield 0.71%. PEG 1.21.
Criteria proven by this page:
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.6 | -0.11 | 5.30 | 0.00 | - |
| 2017 | -10.8 | -7.68 | 5.75 | 0.00 | - |
| 2018 | -3.1 | -0.07 | 4.84 | 102.51 | - |
| 2019 | -7.9 | 0.28 | 7.72 | 14.80 | - |
| 2020 | -11.0 | 0.00 | 11.78 | 19.76 | - |
| 2021 | -7.0 | -0.24 | 7.44 | 16.20 | - |
| 2022 | -5.1 | -6.60 | 27.95 | 10.02 | - |
| 2023 | -5.8 | -0.16 | -13.11 | 14.26 | - |
| 2024 | -12.4 | -2.88 | 39.69 | 31.14 | - |
| 2025 | -29.1 | -1.93 | 50.31 | 61.31 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.85 | $0.00 | $-176.27M | - |
| 2017 | $-2.89 | $0.00 | $-192.65M | - |
| 2018 | $-4.22 | $9.84M | $-324.28M | -3297.2% |
| 2019 | $-3.01 | $136.47M | $-254.34M | -186.4% |
| 2020 | $-3.01 | $164.41M | $-294.09M | -178.9% |
| 2021 | $-3.88 | $188.46M | $-434.65M | -230.6% |
| 2022 | $-3.91 | $245.36M | $-481.53M | -196.3% |
| 2023 | $-5.34 | $305.21M | $-749.57M | -245.6% |
| 2024 | $-5.57 | $363.71M | $-913.77M | -251.2% |
| 2025 | $-6.41 | $606.42M | $-1.28B | -210.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.68 | $-4.21 – $-1.59 | $1.69B | $1.54B – $1.77B | 14 |
| 2027 | $0.87 | $-0.49 – $2.17 | $2.76B | $2.5B – $3B | 13 |
| 2028 | $4.05 | $1.39 – $7.05 | $3.91B | $3.89B – $3.92B | 15 |
| 2029 | $8.43 | $6.84 – $10.49 | $5.19B | $4.44B – $6.17B | 10 |
| 2030 | $10.99 | $8.91 – $13.67 | $6.47B | $5.53B – $7.69B | 6 |
